Vericel
This content is intended for Health Care Professionals in the United States.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. Vericel markets MACI® (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.
For more information, please visit MACI.com.
Vericel
MACI Case Study Discussion: 34yo Male - Trochlear Defect
- 969 views
- July 29, 2024
- 3
Vericel
48yo Female with Cartilage defects of the MFC, Patella & Trochlea - What Would You Do?
- 814 views
- February 7, 2024
- 2
Vericel
Multi-Defect MACI with Concomitant AMZ of an Active 34-year-old Male
- 807 views
- November 29, 2023
- 2
Vericel
HTO and MACI for Treatment of a Medial Femoral Condyle Lesion
- 748 views
- August 30, 2023
- 5
Vericel
20-year-old Female: MACI LFC + Patella With Concomitant TTO, MPFL, and Trochleoplasty
- 1,163 views
- July 26, 2023
- 8
Vericel
30-year-old Female Crossfitter with MFC Cartilage Damage, Lateral Meniscus Root Tear and ACL Graft Tear
- 1,441 views
- June 28, 2023
- 5
Vericel
Case Study: 35 Y.O. Active Female with Left Patellar Pain and Recurring Effusions
- 873 views
- April 27, 2023
- 8
Vericel
MFC and MTP Cartilage Repair with Concomitant HTO and MAT
- 763 views
- February 28, 2023
- 4
Vericel
22-year-old Female with Bilateral Knee Pain: Treatment with MACI & TTO
- 775 views
- February 1, 2023
- 5
Vericel
Case Study: Treatment of Trochlea & Patella Defects with Patellar Maltracking for Female Crossfitter
- 830 views
- January 12, 2022
- 5
INDICATION
MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.
Limitations of Use
- Effectiveness of MACI in joints other than the knee has not been established.
- Safety and effectiveness of MACI in patients over the age of 55 years have not been established.
IMPORTANT SAFETY INFORMATION
Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.
Warnings and Precautions:
- Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be
- Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
- Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI
- Product Sterility: Final sterility test results are not available at the time of shipping.
Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.
Specific Populations:
- Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
- The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.
To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.
For more information or to view Full Prescribing Information, please go to MACI.com.